{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:28:49Z","timestamp":1790494129360,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.vaccine.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T09:08:25Z","timestamp":1528276105000},"page":"4207-4214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults"],"prefix":"10.1016","volume":"36","author":[{"given":"Marc","family":"Baay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaatje","family":"Bollaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Verstraeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.06.004_b0005","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Garcon","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.06.004_b0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1586\/erv.12.35","article-title":"Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines","volume":"11","author":"Alving","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.06.004_b0015","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/14760584.2013.811188","article-title":"An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants","volume":"12","author":"Fox","year":"2013","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.06.004_b0020","unstructured":"Centers for Disease Control and Prevention. FLUAD Flu vaccine with adjuvant: 2015. Accessed: May 8, 2018, https:\/\/www.cdc.gov\/flu\/protect\/vaccine\/adjuvant.htm"},{"key":"10.1016\/j.vaccine.2018.06.004_b0025","unstructured":"NHS England. Update on use of adjuvanted trivalent flu vaccine for 2018-19 flu season: 2017. Accessed: May 8, 2018, https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2017\/12\/2018-19-aTIV-vaccine.pdf"},{"key":"10.1016\/j.vaccine.2018.06.004_b0030","unstructured":"European Medicines Agency. Fendrix, hepatitis B (rDNA) vaccine (adjuvanted, adsorbed). London, : 2005. Accessed: May 8, 2018, http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000550\/human_med_000788.jsp&mid=WC0b01ac058001d124"},{"key":"10.1016\/j.vaccine.2018.06.004_b0035","unstructured":"European Medicines Agency. Cervarix human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed). London, : 2007. Accessed: May 8, 2018, http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000721\/human_med_000694.jsp&mid=WC0b01ac058001d124"},{"key":"10.1016\/j.vaccine.2018.06.004_b0040","unstructured":"European Medicines Agency. Mosquirix H-W-2300. London, : 2015. Accessed: May 8, 2018, http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/document_listing\/document_listing_000395.jsp&mid="},{"key":"10.1016\/j.vaccine.2018.06.004_b0045","unstructured":"European Medicines Agency. Shingrix, herpes zoster vaccine (recombinant, adjuvanted). London, : 2018. Accessed: May 8, 2018, http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/004336\/human_med_002240.jsp&mid=WC0b01ac058001d124"},{"key":"10.1016\/j.vaccine.2018.06.004_b0050","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.vaccine.2015.12.024","article-title":"A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children","volume":"34","author":"Stassijns","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2018.06.004_b0055","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/pds.3554","article-title":"Pooled analysis of large and long-term safety data from the human papillomavirus-16\/18-AS04-adjuvanted vaccine clinical trial programme","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"10.1016\/j.vaccine.2018.06.004_b0060","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/hv.5.5.7211","article-title":"Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials","volume":"5","author":"Descamps","year":"2009","journal-title":"Human Vaccines"},{"key":"10.1016\/j.vaccine.2018.06.004_b0065","unstructured":"European Medicines Agency. Summary of the risk management plan (RMP) for Mosquirix (plasmodium falciparum and hepatitis B vaccine, recombinant, adjuvanted): 2015. Accessed: May 11, 2018, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_for_use_outside_EU\/2015\/07\/WC500190200.pdf"},{"key":"10.1016\/j.vaccine.2018.06.004_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033536","article-title":"AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland","volume":"7","author":"Nohynek","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.06.004_b0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/joim.12150","article-title":"Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up","volume":"275","author":"Persson","year":"2014","journal-title":"J Internal Med"},{"key":"10.1016\/j.vaccine.2018.06.004_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149289","article-title":"Application of probabilistic multiple-bias analyses to a cohort- and a case-control study on the association between pandemrix and narcolepsy","volume":"11","author":"Bollaerts","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.06.004_b0085","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statist Med"},{"key":"10.1016\/j.vaccine.2018.06.004_b0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical trials"},{"key":"10.1016\/j.vaccine.2018.06.004_b0095","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2018.06.004_b0100","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.06.004_b0105","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0110","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2018.06.004_b0115","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 Years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2018.06.004_b0120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.vaccine.2013.10.052","article-title":"Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials","volume":"33","author":"Leroux-Roels","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0125","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/CVI.00807-13","article-title":"Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults","volume":"21","author":"Pauksens","year":"2014","journal-title":"Clin Vaccine Immunol : CVI"},{"key":"10.1016\/j.vaccine.2018.06.004_b0130","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.vaccine.2008.02.068","article-title":"Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial","volume":"26","author":"Rumke","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0135","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/infdis\/jiq174","article-title":"Immunogenicity profile of a 3.75-mug hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial","volume":"203","author":"Heijmans","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.06.004_b0140","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/1745-6215-15-419","article-title":"Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study","volume":"15","author":"Gillard","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.vaccine.2018.06.004_b0145","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 A\/Indonesia\/05\/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study","volume":"203","author":"Langley","year":"2011","journal-title":"The Journal of infectious diseases."},{"key":"10.1016\/j.vaccine.2018.06.004_b0150","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1473-3099(13)70046-X","article-title":"AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial","volume":"13","author":"McElhaney","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.06.004_b0155","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/infdis\/jir641","article-title":"Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant","volume":"205","author":"Ferguson","year":"2012","journal-title":"J Infect Di"},{"key":"10.1016\/j.vaccine.2018.06.004_b0160","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1016\/j.vaccine.2013.07.007","article-title":"Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial","volume":"31","author":"Yang","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0165","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0264-410X(98)00185-6","article-title":"Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons","volume":"17","author":"Minutello","year":"1999","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2018.06.004_b0170","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1016\/S0264-410X(99)00138-3","article-title":"Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly","volume":"17","author":"De Donato","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1017919305501","article-title":"Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects","volume":"17","author":"Gasparini","year":"2001","journal-title":"Europ J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.06.004_b0180","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0264-410X(02)00401-2","article-title":"Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects","volume":"21","author":"Squarcione","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0185","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s15010-004-3204-z","article-title":"Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly","volume":"32","author":"Ruf","year":"2004","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2018.06.004_b0190","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1742-4933-5-2","article-title":"Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects","volume":"5","author":"Li","year":"2008","journal-title":"Immunity Ageing : I & A."},{"key":"10.1016\/j.vaccine.2018.06.004_b0195","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4161\/hv.18445","article-title":"Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 ((R)) adjuvant: results from a dose-finding clinical trial in older adults","volume":"8","author":"Della Cioppa","year":"2012","journal-title":"Human Vaccines Immunotherapeut"},{"key":"10.1016\/j.vaccine.2018.06.004_b0200","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1016\/j.vaccine.2014.07.013","article-title":"Comparison of the safety and immunogenicity of an MF59(R)-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0205","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1128\/CVI.00615-13","article-title":"Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly","volume":"21","author":"Seo","year":"2014","journal-title":"Clin Vaccine Immunol : CVI."},{"key":"10.1016\/j.vaccine.2018.06.004_b0210","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.4161\/hv.25580","article-title":"Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison","volume":"9","author":"Scheifele","year":"2013","journal-title":"Human Vaccines Immunotherapeut"},{"key":"10.1016\/j.vaccine.2018.06.004_b0215","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1016\/j.vaccine.2015.05.003","article-title":"Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults","volume":"33","author":"Song","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0220","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2016.11.047","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in 60-year-old adults","volume":"35","author":"Song","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2018.06.004_b0230","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40\u201370 years of age","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0235","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/S0264-410X(03)00251-2","article-title":"Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents","volume":"21","author":"Ben-Yehuda","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0240","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0264-410X(01)00253-5","article-title":"Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide","volume":"20","author":"Hedlund","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0245","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0047-6374(96)01809-X","article-title":"Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults","volume":"93","author":"Powers","year":"1997","journal-title":"Mech Age Development"},{"key":"10.1016\/j.vaccine.2018.06.004_b0250","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.vaccine.2012.06.009","article-title":"Randomized clinical trial of immunogenicity and safety of a recombinant H1N1\/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant","volume":"30","author":"Gordon","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0255","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1016\/S0264-410X(01)00060-3","article-title":"Comparison of three different influenza vaccines in institutionalised elderly","volume":"19","author":"Baldo","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0260","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(94)92758-8","article-title":"Immunogenicity of new virosome influenza vaccine in elderly people","volume":"344","author":"Gluck","year":"1994","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.vaccine.2018.06.004_b0265","first-page":"1417","article-title":"Assessing and measuring chronic multimorbidity in the older population: a proposal for its operationalization","volume":"72","author":"Calderon-Larranaga","year":"2017","journal-title":"J Gerontology Series A, Biol Sci Med Sci"},{"key":"10.1016\/j.vaccine.2018.06.004_b0270","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1016\/j.vaccine.2011.08.016","article-title":"Safety of pandemic H1N1 vaccines in children and adolescents","volume":"29","author":"Wijnans","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.004_b0275","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.vaccine.2011.02.097","article-title":"Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination","volume":"29","author":"Parretta","year":"2011","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18308156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18308156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:25:54Z","timestamp":1759400754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18308156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":55,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0264410X18308156"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.004","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}